Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer
- 15 June 1994
- journal article
- clinical trial
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 29 (3), 611-616
- https://doi.org/10.1016/0360-3016(94)90467-7
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: Results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1992
- The effect of local control on metastatic dissemination in carcinoma of the prostate: Long-term results in patients treated with 1251 implantationInternational Journal of Radiation Oncology*Biology*Physics, 1991
- Prostatc specific antigen as an indicator of response to radiotherapy in prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: Preliminary results of RTOG 83-07International Journal of Radiation Oncology*Biology*Physics, 1989
- A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United StatesInternational Journal of Radiation Oncology*Biology*Physics, 1987
- Phase I trial of the hypoxic cell radiosensitizer SR-2508: The results of the five to six week drug scheduleInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Tumor control in definitive irradiation of localized carcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Radiosensitization of hypoxic cells in vivo by SR 2508 at low radiation doses: A preliminary reportInternational Journal of Radiation Oncology*Biology*Physics, 1984
- Carcinoma of the prostate: Results of post‐irradiation biopsyThe Prostate, 1984
- SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical useInternational Journal of Radiation Oncology*Biology*Physics, 1981